Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

被引：0

作者：

van de Donk, Niels W. C. J.

Garfall, Alfred L.

Benboubker, Lotfi

Uttervall, Katarina

Groen, Kaz

Rosinol, Laura

Matous, Jeffrey V.

Vishwamitra, Deeksha

Hodin, Caroline

Stephenson, Tara

Qi, Keqin

Zuppa, Athena

Chastain, Katherine

Mateos, Maria-Victoria

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France

[4] Karolinska Univ Hosp, Stockholm, Sweden

[5] Vrije Univ, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[6] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[7] Colorado Blood Canc Inst, Denver, CO USA

[8] Sarah Cannon Res Inst, Denver, CO USA

[9] Johnson & Johnson Innovat Med, Spring House, PA USA

[10] Johnson & Johnson Innovat Med, Antwerp, Belgium

[11] Johnson & Johnson Innovat Med, Titusville, NJ USA

[12] Johnson & Johnson Innovat Med, Raritan, NJ USA

[13] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC USAL, CSIC, Salamanca, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7517

引用

页数：1

共 50 条

[41] OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Rifkin, Robert M.
Schade, Henning Helmut
Simmons, Gary
Yasenchak, Christopher A.
Fowler, Jessica
Lin, Thomas S.
Thomson, Brian
Xu, Weiming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Final Results from the First-in -Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Vogl, Dan T.
Atrash, Shebli
Holstein, Sarah A.
Nadeem, Omar
Benson, Don M.
Suryanarayan, Kaveri
Liu, Yuyin
Collins, Sabrina
Parot, Xavier
Kaufman, Jonathan L.
BLOOD, 2022, 140 : 1357 - 1359
[43] Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
Hari, Parameswaran
Nguyen, Andy
Pelletier, Corey
McGarvey, November
Gitlin, Matthew
Parikh, Kejal
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
[44] Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients
Frigault, Matthew
Rosenblatt, Jacalyn
Dhakal, Binod
Raje, Noopur
Cook, Daniella
Gaballa, Mahmoud
Emmanuel-Alejandro, Estelle
Nissen, Danielle
Banerjee, Kamalika
Rotte, Anand
Heery, Christopher
Avigan, David
Jakubowiak, Andrzej
Bishop, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S553 - S553
[45] Phase 1 Study Of Anitocabtagene Autoleucel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients
Frigault, Matthew
Rosenblatt, Jacalyn
Dhakal, Binod
Raje, Noopur
Cook, Danielle
Gaballa, Mahmoud
Emmanuel-Alejandro, Estelle
Nissen, Danielle
Banerjee, Kamalika
Rotte, Anand
Heery, Christopher
Avigan, David
Jakubowiak, Andrzej
Bishop, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S19 - S20
[46] FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
Jakubowiak, A. J.
Rosenbaum, C. A.
Stephens, L.
Kukreti, V.
Cole, C.
Zimmerman, T.
Reece, D.
Berdeja, J.
Severson, E.
Wolfe, B.
Major, S.
McDonnell, K.
Nam, J.
Turowski, A.
Griffith, K.
Zonder, J.
HAEMATOLOGICA, 2017, 102 : 271 - 271
[47] Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
Frigault, Matthew J.
Rosenblatt, Jacalyn
Dhakal, Binod
Raje, Noopur S.
Cook, Daniella
Gaballa, Mahmoud
Emmanuel-Alejandro, Estelle
Nissen, Danielle
Banerjee, Kamalika C.
Rotte, Anand
Heery, Christopher R.
Avigan, David
Jakubowiak, Andrzej J.
Bishop, Michael R.
BLOOD, 2023, 142
[48] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Jagannath, S.
Moreau, P.
Jakubowiak, A. J.
Facon, T.
Vij, R.
White, D.
Reece, D. E.
Benboubker, L.
Zonder, J.
Tsao, L. C.
Anderson, K. C.
Bleickardt, E.
Singhal, A. K.
Lonial, S.
Oncology Research and Treatment, 2015, 38 : 165 - 165
[49] Three- Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Fu, Chengcheng
Chen, Wenming
Cai, Zhen
Yan, Lingzhi
Wang, Huijuan
Shang, Jingjing
Wu, Yin
Yan, Shuang
Gao, Wen
Shi, Xiaolan
Han, Xiaoyan
Tang, Fang
Zheng, Gaofeng
Wen, Yanling
Meng, Xingxing
Zheng, Wei
Wang, Huamao
Li, Zonghai
BLOOD, 2023, 142
[50] Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
Spencer, Andrew
Iversen, Katrine Fladeland
Dhakal, Binod
Creignou, Maria
Chen, Jenny
Hiemstra, Ida H.
Bosgra, Sieto
Badani, Avani
Breij, Esther C. W.
Brady, Lauren K.
Sasser, A. Kate
Malmberg, Anders
Gregersen, Henrik
Hansson, Markus
Broijl, Annemiek
Mateos, Maria-Victoria
Plesner, Torben
BLOOD, 2022, 140 : 7320 - 7321

← 1 2 3 4 5 →